JP2011528030A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528030A5
JP2011528030A5 JP2011518009A JP2011518009A JP2011528030A5 JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5 JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528030A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/050856 external-priority patent/WO2010007427A1/en
Publication of JP2011528030A publication Critical patent/JP2011528030A/ja
Publication of JP2011528030A5 publication Critical patent/JP2011528030A5/ja
Pending legal-status Critical Current

Links

JP2011518009A 2008-07-16 2009-07-15 ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用 Pending JP2011528030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8121308P 2008-07-16 2008-07-16
US61/081,213 2008-07-16
PCT/GB2009/050856 WO2010007427A1 (en) 2008-07-16 2009-07-15 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases

Publications (2)

Publication Number Publication Date
JP2011528030A JP2011528030A (ja) 2011-11-10
JP2011528030A5 true JP2011528030A5 (enExample) 2012-08-30

Family

ID=41011976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518009A Pending JP2011528030A (ja) 2008-07-16 2009-07-15 ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用

Country Status (13)

Country Link
US (1) US20100016275A1 (enExample)
EP (1) EP2315754A1 (enExample)
JP (1) JP2011528030A (enExample)
KR (1) KR20110031462A (enExample)
CN (1) CN102159555A (enExample)
AR (1) AR072818A1 (enExample)
AU (1) AU2009272425B2 (enExample)
BR (1) BRPI0915908A2 (enExample)
CA (1) CA2730477A1 (enExample)
MX (1) MX2011000402A (enExample)
RU (1) RU2011101661A (enExample)
TW (1) TW201006824A (enExample)
WO (1) WO2010007427A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2408587C2 (ru) * 2004-08-24 2011-01-10 Астразенека Аб Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
WO2012007748A1 (en) 2010-07-13 2012-01-19 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) * 2011-07-12 2016-10-17 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
BR112014019180A8 (pt) * 2012-02-07 2017-07-11 Hoffmann La Roche Novos derivados de azetidina
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP3426253A4 (en) 2016-03-11 2019-11-06 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF CRYSTALARTHROPATHIES

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540356A (en) * 1949-03-12 1951-02-06 Sharp & Dohme Inc Sulfonamide derivatives
GB866843A (en) * 1958-12-08 1961-05-03 Ici Ltd Sulphonamidopyrimidines
NL279406A (enExample) * 1961-06-16
NL127990C (enExample) * 1962-12-29
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
US3452018A (en) * 1966-08-29 1969-06-24 American Home Prod 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004018435A1 (en) * 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
RU2408587C2 (ru) * 2004-08-24 2011-01-10 Астразенека Аб Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
JP2006137723A (ja) * 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体

Similar Documents

Publication Publication Date Title
JP2011528030A5 (enExample)
JP2013542261A5 (enExample)
JP5833764B2 (ja) 縮合環を有するオキサゾリドン(oxazolidone)類の抗菌物質
TW202417442A (zh) 苯甲醯胺化合物
JP2018515495A5 (enExample)
JP2014524442A5 (enExample)
HRP20161696T4 (hr) Tenofovir alafenamid hemifumarat
JP2011528658A5 (enExample)
JP2009537498A5 (enExample)
JP2013518107A5 (enExample)
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
EP2760285A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN103249697A (zh) 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物
JP2018517686A5 (enExample)
JP2006504766A5 (enExample)
JP2020536893A5 (enExample)
JP2014525470A5 (enExample)
JP2010535755A (ja) イミダゾピリジノン
JP2015522589A5 (enExample)
JP2017531619A5 (enExample)
EA009941B1 (ru) Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
RU2022109286A (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
WO2018234978A1 (en) Substituted 5-cyanoindole compounds and uses thereof
JP2012533550A5 (enExample)
CN1443168A (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法